Abstract
The therapeutic efficacy, safety and usefulness of emedastine difumarate (DAREN) given at doses from 2 to 4 mg/day for 8 weeks to patients with severe perennial allergic rhinitis were investigated.
Among a total of 36 patients enrolled, 34 patients were evaluated for efficacy and usefulness, 36 for safety.
The results were as follows.
1) In the final global improvement rating, 28 of 34 cases (82.4%) were assessed as “moderately improved” or more.
2) In 29 of 34 patients (85.3%), the severity of the subjective and objective (nasal) symptoms were ameliorated from “severe” to “slight” or “none”.
3) In the overall safety rating, the percentage of cases evaluated as “no adverse reaction and safe” was 88.9%.
4) Adverse reactions were observed in 4 cases (11.1%), of which drowsiness was the reaction (3 cases).
Administration was, however, continued in all cases throughout the study period, because the side-effects were mild and not clinically serious.
5) In the usefulness rating, the treatment was rated as “fairly useful” or better in 76.5% (26/34), of the cases.
In conclusion, DAREN is considered to be markedly effective, safe and useful in the treatment of severe perennial allergic rhinitis.
